Drug Makers Shifting Towards Targeted Cancer Drugs

Digital patient profiles and expansive real-world data are reshaping oncology clinical trials, explained Gen Li, PhD, MBA, president and founder of Phesi.

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

Researchers at Sylvester Comprehensive Cancer Center reveal how body composition analysis predicts treatment response in diffuse large B-cell lymphoma (DLBCL), enhancing precision medicine strategies.

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.

In a large fecal immunochemical test-based screening program, high adenoma detection rates lowered interval colorectal cancer (CRC) incidence and mortality, but not CRC-specific survival.